Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

NCT ID: NCT03556891

Last Updated: 2025-10-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

133 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-04

Study Completion Date

2024-09-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy or 52 weeks of implantation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study enrolled and implanted 133 subjects at 15 sites in the US under the original IDE.

Subjects were given the option to extend out to 3 years post activation, with annual visits at 2 and 3 years post activation (96 and 144 weeks post-activation).

Subjects who are still active in the original IDE study will be offered consecutive enrollment in the post approval study and will be given the option to receive a new implant. Subjects who are no longer active, or have exited the study will be given the option to reenter the study and complete two follow-up visits. Subjects re-entering the study will not have the option to receive a new implant. Post approval follow-up of subjects will occur through the year 5 visit (257 weeks post-activation of their original device). Reimplantation of a new eCoin would not reset their follow-up clock.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder Urge Incontinence Incontinence, Urinary Urinary Urge Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

eCoin Tibial Nerve Stimulation

Group Type EXPERIMENTAL

eCoin Tibial Nerve Stimulation

Intervention Type DEVICE

Subcutaneous stimulation of the tibial nerve using the eCoin device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

eCoin Tibial Nerve Stimulation

Subcutaneous stimulation of the tibial nerve using the eCoin device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women and men between 18 and 80 years old.
2. Diagnosis of overactive bladder with urgency urinary incontinence or mixed urge and stress incontinence with a predominant urgency component (selfreported), for at least 6 months.
3. Individual is without pharmacological treatment of overactive bladder (antimuscarinics and beta-3 agonists).
4. Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or percutaneous tibial nerve stimulation.

Exclusion Criteria

1. Predominant stress urinary incontinence with more than 1/3 stress urinary incontinent episodes when compared to total urinary incontinent episodes.
2. Clinically significant bladder outlet obstruction.
3. Clinically significant pelvic organ prolapse beyond the hymenal ring.
4. Inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Valencia Technologies Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Scott MacDiarmid, MD

Role: PRINCIPAL_INVESTIGATOR

Alliance Urology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kaiser Permanente

Downey, California, United States

Site Status

Sequoia Urology Center

Redwood City, California, United States

Site Status

Kaiser Permanente

San Diego, California, United States

Site Status

Sansum Clinic

Santa Barbara, California, United States

Site Status

SurgOne PC

Englewood, Colorado, United States

Site Status

Urology Associates of Norwalk

Norwalk, Connecticut, United States

Site Status

Florida Bladder Institute

Naples, Florida, United States

Site Status

North Shore Medical Group

Skokie, Illinois, United States

Site Status

UnityPoint Clinic

Waterloo, Iowa, United States

Site Status

Chesapeake Urology

Owings Mills, Maryland, United States

Site Status

Adult & Pediatric Urology

Omaha, Nebraska, United States

Site Status

Manhattan Medical Research

New York, New York, United States

Site Status

Alliance Urology Specialists

Greensboro, North Carolina, United States

Site Status

The Institute for Female Pelvic Medicine & Reconstructive Surgery (FPM Institute)

Allentown, Pennsylvania, United States

Site Status

South Carolina OB/GYN

Columbia, South Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

111-3281

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

INTIBIA Pivotal Study
NCT05250908 ACTIVE_NOT_RECRUITING NA